Understanding how certain proteins increase the risk of severe allergic reactions in children
TPSAB1-derived tryptases promote myeloproliferation and anaphylaxis
This study is looking at how a protein called TPSAB1 might make kids with allergies more likely to have severe reactions, like anaphylaxis, and aims to find ways to help prevent these dangerous situations by understanding how this protein affects their immune system.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11080932 on NIH RePORTER |
What this research studies
This research investigates the role of a specific protein, TPSAB1, in increasing the risk of severe allergic reactions, particularly anaphylaxis, in sensitized individuals, especially children. The study aims to identify how elevated levels of this protein affect immune cells and their interactions, potentially leading to dangerous allergic responses. By understanding these mechanisms, the researchers hope to develop targeted therapies that can prevent or mitigate the severity of anaphylactic reactions. The approach includes analyzing gene expression and the behavior of immune cells in response to increased TPSAB1 levels.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under 11 years old who have a history of severe allergic reactions or anaphylaxis.
Not a fit: Patients who do not have allergies or those over the age of 11 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce the risk and severity of anaphylaxis in allergic individuals.
How similar studies have performed: Previous research has shown promising results in understanding the role of biomarkers in allergic reactions, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Lyons, Jonathan — University of California, San Diego
- Study coordinator: Lyons, Jonathan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.